Qutenza + Pregabalin
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Non-diabetic Painful Peripheral Polyneuropathy
Conditions
Non-diabetic Painful Peripheral Polyneuropathy, Postherpetic Neuralgia (PHN), Peripheral Nerve Injury (PNI)
Trial Timeline
Jul 11, 2012 → Sep 26, 2013
NCT ID
NCT01713426About Qutenza + Pregabalin
Qutenza + Pregabalin is a approved stage product being developed by Astellas Pharma for Non-diabetic Painful Peripheral Polyneuropathy. The current trial status is completed. This product is registered under clinical trial identifier NCT01713426. Target conditions include Non-diabetic Painful Peripheral Polyneuropathy, Postherpetic Neuralgia (PHN), Peripheral Nerve Injury (PNI).
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01713426 | Approved | Completed |
Competing Products
3 competing products in Non-diabetic Painful Peripheral Polyneuropathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Candesartan Cilexetil + Candesartan Cilexetil + Candesartan Cilexetil 32mg | AstraZeneca | Approved | 85 |
| Aliskiren + Placebo to Aliskiren + Hydrochlorothiazide (HCTZ) + Placebo to Hydrochlorothiazide (HCTZ) + Ramipril | Novartis | Phase 2 | 52 |
| Finerenone (BAY94-8862) + Placebo | Bayer | Phase 3 | 74 |